Agbo F, Crass RL, Chiu YY, Chapel S, Galluppi G, Blum D, Navia B. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease. Clin Transl Sci. 2021; 14:(4)1464-1475

Alonso-Canovas A, Martínez-Castrillo JC. Apomorfina: un poderoso aliado en la enfermedad de Parkinson (Apomorphine: a powerful ally in Parkinson's disease). Rev Neurol. 2021; 72:(9)323-332

Aronson JK. Apomorphine.: Elsevier; 2016

Auffret M, Drapier S, Vérin M. The many faces of apomorphine: lessons from the past and challenges for the future. Drugs R D. 2018; 18:(2)91-107

Borkar N, Mu H, Holm R. Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease. Asian J Pharm Sci. 2018; 13:(6)507-517

Boyle A, Ondo W. Role of apomorphine in the treatment of Parkinson's disease. CNS Drugs. 2015; 29:(2)83-9

Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019; 33:(9)905-918

Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol. 1994; 17:(3)243-59

Dewey RB, Maraganore D, Ahlskog JE, Matsumoto J. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov Disord. 1998; 13:(5)782-787

Duncan D. Role of the community nurse in Parkinson's disease and lower urinary disorders. Br J Community Nurs. 2021; 26:(5)251-254

Factor SA. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics. 2008; 5:(2)164-80

FDA. KYNMOBI™ (apomorphine hydrochloride) sublingual film. 2020. (accessed 19 June 2022)

Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990; 53:(2)96-101

Gibb WRG, Lees AJ. Alzheimer pathology in Parkinson's disease. Neurology. 1989; 39:(6)874-874

Grover S, Sathpathy A, Reddy SC, Mehta S, Sharma N. Parkinsonism-hyperpyrexia syndrome: a case report and review of literature. Indian J Psychiatry. 2018; 60:(4)499-503

Gülke E, Pötter-Nerger M. Caregiver Burden in Partners of Parkinsonian Patients with Deep Brain Stimulation. Brain Sci. 2022; 12:(2)

Hui JS, Fox SH, Neeson W, Bhargava P, Pappert E, Blum D, Navia B Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and “OFF” episodes. Parkinsonism Relat Disord. 2020; 79:110-116

Katzenschlager R, Poewe W, Rascol O Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021; 83:79-85

Kynmobi. Highlights of prescribing information. 2021. (accessed 29 April 2022)

Little S, Brown P. Debugging adaptive deep brain stimulation for Parkinson's Disease. Mov Disord. 2020; 35:(4)555-561

Understanding quality in district nursing services learning from patients, carers and staff. 2016. (accessed 8 June 2022)

McCrory V. An overview of the role of the district nurse caring for individuals with complex needs. Br J Community Nurs. 2019; 24:(1)20-26

Medline. Apomorphine injection: MedlinePlus drug information. 2019. (Accessed 14 Feb. 2022)

Meira B, Degos B, Corsetti E Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study. npj Parkinsons Dis. 2021; 7

Moffat P. District nurse workforce decline. Practice Management. 2019; 29:5-5

Molina JA, Sáinz-Artiga MJ, Fraile A, Jiménez-Jiménez FJ, Villanueva C, Ortí-Pareja M, Bermejo P F. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Movement Disorders. 2000; 15:(5)869-72

National Institute for Health and Care Excellence. Recommendations: Parkinson's disease in adults - guidance. 2017. (accessed 17 June 2022)

National Institute for Health and Care Excellence. BNF is only available in the UK. 2022. (accessed 29 April 2022)

Nursing and Midwifery Council. Standards for medicines management. 2019.

Olanow CW, Factor SA, Espay AJ Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020; 19:(2)135-144

Queen's Nursing Institute. Transition to district nursing service contents. 2017. (accessed 15 July 2019)

Rosa-Grilo M, Qamar MA, Evans A, Chaudhuri KR. The efficacy of apomorphine - a non-motor perspective. Parkinsonism Relat Disord. 2016; 33:(S1)S28-S35

Royal College of Nursing. Urgent need for more investment in the district nursing service, nursing bodies warn. 2019. (accessed 12 March 2020)

Royal Pharmaceutical Society. Professional guidance on the administration of medicines in healthcare settings. 2019. (accessed 19 Junes 2022)

Schwab RS, Prichard JS. An assessment of therapy in Parkinson's disease. AMA Arch Neurol Psychiatry. 1951; 65:(4)489-502

Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988; 1:(8582)403-406

Sunovian. Sunovion and bial enter european licensing agreement for apomorphine sublingual film for the treatment of Parkinson's Disease off episodes. 2021. (accessed 19 June 2022)

Svenningsson P, Pålhagen S, Mathé AA. Neuropeptide Y and calcitonin gene-related peptide in cerebrospinal fluid in Parkinson's Disease with comorbid depression versus patients with major depressive disorder. Front Psychiatry. 2017; 8

Titova N, Chaudhuri KR. Apomorphine therapy in Parkinson's and future directions. Parkinsonism Relat Disord. 2016; 33:(S1)S56-S60

Todd A, James CA. Apomorphine nodules in Parkinson's disease: best practice considerations. Br J Community Nurs. 2008; (10)457-463

Trenkwalder C, Chaudhuri KR, García Ruiz PJ Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--clinical practice recommendations. Parkinsonism Relat Disord. 2015; 21:(9)1023-30

Weil E. De l'apomorphine dans certain troubles nerveux. Lyon Med. 1884; 48:411-419

Sublingual apomorphine therapy as an alternative to complex continuous infusion pumps in advanced Parkinson's disease treatment: a district nurse-led intervention

02 July 2022
Volume 27 · Issue 7


In the UK, Parkinson's disease (PD) is estimated to affect an annual incidence of 15–20 per 100 000 of the population over the age of 60. Service users living with advanced-stage PD require the use of apomorphine, which is generally used to control symptoms. The district nursing service plays a key role in monitoring and in the administration of apomorphine therapy. Although apomorphine is effective, skin problems such as nodules are commonly reported adverse events that can complicate efficiency of treatment. A sublingual delivery route to apomorphine has been known for years as a feasible alternative to subcutaneous route. Collaboration between the multidisciplinary team is essential to meet the complex needs of service users with advanced PD. However, due to the increase in demands of the district nurse service, this time crucial intervention can be unpredictable to meet. An alternative route can enable district nurses to become less task-orientated. However, an increased risk of oral cavity related adverse events should be taken into consideration with the sublingual administration of apomorphine.

In the UK, Parkinson's disease (PD) is estimated to have an annual incidence of 15–20 per 100 000 of the population over the age of 60 (Meira et al, 2021). Parkinson's is an incapacitating disease and categorised by long-lasting neurodegeneration of the striatal region of the brain that causes the absence of neurotransmitter dopamine (Borkar et al, 2018). The condition may progress to cause life–debilitating impairments, which can have a negative impact on quality of life and indirectly to those surrounding the individual, such as family and carers (Boyle and Ondo, 2015). PD is untreatable; however, a range of symptomatic treatments are available to develop the quality of life as well as longevity for the advanced PD service user, and research has shown apomorphine to be an effective treatment to manage those symptoms (Alonso-Canovas and Martinez-Castrillo, 2021).

Register now to continue reading

Thank you for visiting Community Nursing and reading some of our peer-reviewed resources for district and community nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month